The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 15, 2021
Filed:
Nov. 13, 2017
Applicant:
Sagimet Biosciences Inc., San Mateo, CA (US);
Inventors:
Douglas I. Buckley, San Mateo, CA (US);
Gregory Duke, San Mateo, CA (US);
Allan S. Wagman, Belmont, CA (US);
Marc Evanchik, San Jose, CA (US);
Robert S. McDowell, San Francisco, CA (US);
Assignee:
Saginiet Biosciences Inc., San Mateo, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/445 (2006.01); C07D 471/04 (2006.01); A61P 1/16 (2006.01); A61P 31/14 (2006.01); A61P 35/00 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01); C07D 491/052 (2006.01); C07D 491/107 (2006.01); C07D 513/04 (2006.01); C07D 401/10 (2006.01); C07D 487/10 (2006.01); C07D 211/38 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61P 1/16 (2018.01); A61P 31/14 (2018.01); A61P 35/00 (2018.01); C07D 211/38 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 491/052 (2013.01); C07D 491/107 (2013.01); C07D 513/04 (2013.01);
Abstract
Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).